Observational studyBMC infectious diseases2026
The value of interleukin-6 (IL-6), neuropilin-1 (Nrp-1) and amphiregulin (AREG) levels in predicting mortality in patients admitted to the intensive care unit with a pre-diagnosis of sepsis or septic shock.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis and septic shock are associated with high ICU mortality, and early risk stratification remains challenging. We assessed whether admission serum interleukin-6 (IL-6), neuropilin-1 (Nrp-1), and amphiregulin (AREG) predict 28- and 90-day mortality in ICU patients meeting Sepsis-3 criteria.
methodsIn this prospective single-center observational study, 100 adults with sepsis (n = 59) or septic shock (n = 41) were enrolled; 60 healthy volunteers provided exploratory reference values only. Serum IL-6, Nrp-1, and AREG were measured by ELISA within 24 h of ICU admission. The primary outcomes were 28-day and 90-day mortality. Discrimination was assessed with receiver operating characteristic (ROC) analysis and cut-offs were derived using the Youden index. Multivariable logistic regression was used to identify independent predictors of 90-day mortality.
resultsAdmission Nrp-1 was higher in non-survivors at both 28 and 90 days and showed modest discrimination (AUC 0.650 and 0.627, respectively). Youden cut-offs were 235 pg/mL for 28-day mortality and 165 pg/mL for 90-day mortality. In multivariable analysis, Nrp-1 (aOR 1.004 per 1 pg/mL; ~1.49 per 100 pg/mL), age, SOFA score, and non-urogenital infection focus were independently associated with 90-day mortality; the combined model demonstrated moderate discrimination (AUC 0.793). IL-6 and AREG were not associated with 28-day or 90-day mortality.
conclusionsAdmission Nrp-1 may provide adjunct prognostic information but its standalone performance is modest; it should be interpreted alongside established clinical risk scores. External validation in larger multicenter cohorts, preferably with serial measurements, is warranted. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.